A Systematic Review of Circulating Tumor Cells in Renal Cell Carcinoma

سال انتشار:

1400

نوع سند:

مقاله ژورنالی

زبان:

انگلیسی

مشاهده:

151

فایل این مقاله در 9 صفحه با فرمت PDF قابل دریافت می باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

JR_TUMS-3-1_003

تاریخ نمایه سازی: 17 فروردین 1400

چکیده مقاله:

Introduction Renal cell carcinoma (RCC) is one of the most usual kidney’s tumors. The improvement of non-invasive biomarkers will make it feasible to investigate whose have high risk of recurrence after radical or partial nephrectomy and will expand the valuation of tumor response to several treatment strategies. In this perspective, liquid biopsy suggests a talented perception for cancer diagnosis and monitoring, with several benefits versus traditional RCC diagnostic processes and can be taken into account of the present RCC diagnosis and controlling strategies. Method In this systematic review, we considered both CTCs count and molecular markers in RCC patient management. A systematic search on several databases like PubMed, Scopus, Embase, and Web of Science was directed which led to the final 24 studies considering the impact of CTCs on both diagnosis and prognosis of RCC. Results Several primary studies consider the CTCs quantitation as the tumor representing components that are based on immunomagnetic separation procedure. The magnetic cell sorting (MACS) technique, cell search, Tapered-slit filter (photosensitive polymer-based microfilter), CELLection™ Dynabeads® coated with the monoclonal antibodies, and ISET® -Isolation by Size of Tumor cells.  If CTCs wanted to be recruited for the prognosis of RCC and progression-free survival (PFS) it is better to check by gene expression profile through quantitative polymerase chain reaction analysis (Real Time-PCR) or in situ hybridization of CTC’s RNA molecules.   Conclusions CTCs detection as the main liquid biopsy component has an excessive clinical impact on cancer management. Nevertheless, usual methods have some limitations when directing for the recognition of circulating tumor cells (CTCs) with high efficiency and low cost. Some CTCs molecular markers and gene expression profiling of CTCs should be considered for RCC prognosis. 

نویسندگان

FatemehKhatami
Fatemeh Khatami

Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran

MohadesehNasir Shirazi
Mohadeseh Nasir Shirazi

Monoclonal antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran

Seyed Mohammad KazemAghamir
Seyed Mohammad Kazem Aghamir

Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran

مراجع و منابع این مقاله:

لیست زیر مراجع و منابع استفاده شده در این مقاله را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود مقاله لینک شده اند :
  • 1.Prasad SR, Humphrey PA, Catena JR, Narra VR, Srigley JR, ...
  • 2.Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK. Rising incidence ...
  • 3.Wahner-Roedler DL, Sebo TJ, editors. Renal cell carcinoma: diagnosis based ...
  • 4.Yamamoto Y, Uemura M, Nakano K, Hayashi Y, Wang C, ...
  • 5.Barwari K, de la Rosette JJ, Laguna MP. The penetration ...
  • 6.García-Casas A, García-Olmo DC, García-Olmo D. Further the liquid biopsy: ...
  • 7.Santoni M, Cimadamore A, Cheng L, Lopez-Beltran A, Battelli N, ...
  • 8.Di Meo A, Bartlett J, Cheng Y, Pasic MD, Yousef ...
  • 9.Reduzzi C, Vismara M, Gerratana L, Silvestri M, De Braud ...
  • 10.Apolo AB, Mortazavi A, Hu ZI, Schonhoft J, Chu L, ...
  • 11.Bilkenroth U, Taubert H, Riemann D, Rebmann U, Heynemann H, ...
  • 12.Bluemke K, Bilkenroth U, Meye A, Fuessel S, Lautenschlaeger C, ...
  • 13.Blümke K, Bilkenroth U, Schmidt U, Melchior A, Füssel S, ...
  • 14.Broncy L, Njima BB, Méjean A, Béroud C, Romdhane KB, ...
  • 15.El-Heliebi A, Kroneis T, Zöhrer E, Haybaeck J, Fischereder K, ...
  • 16.Gradilone A, Iacovelli R, Cortesi E, Raimondi C, Gianni W, ...
  • 17.Kim TH, Kang Y-T, Cho Y-H, Kim JH, Jeong BC, ...
  • 18.Kolostova K, Cegan M, Bobek V. Circulating tumour cells in ...
  • 19.LI G, PASSEBOSC-FAURE K, GENTIL-PERRET A, LAMBERT C, GENIN C, ...
  • 20.Liu M, Li R, Tang Y, Chang J, Han R, ...
  • 21.Liu S, Tian Z, Zhang L, Hou S, Hu S, ...
  • 22.Nel I, Gauler TC, Bublitz K, Lazaridis L, Goergens A, ...
  • 23.Rossi E, Fassan M, Aieta M, Zilio F, Celadin R, ...
  • 24.Shimazui T, Yoshikawa K, Uemura H, Hirao Y, Saga S, ...
  • 25.Wang Z-L, Zhang P, Li H-C, Yang X-J, Zhang Y-P, ...
  • 26.Yang X, Zhang D, Chong T, Li Y, Wang Z, ...
  • 27.Zhang T, Boominathan R, Foulk B, Rao C, Kemeny G, ...
  • 28.Zhu P, Stanton ML, Castle EP, Joseph RW, Adams DL, ...
  • 29.Zou J, Wang E. eTumorType, An algorithm of discriminating cancer ...
  • 30.Bai M, Zou B, Wang Z, Li P, Wang H, ...
  • 31.Lee RT, Fallarino F, Ashikari A, Gajewski TF. Melanoma presenting ...
  • 32.Maertens Y, Humberg V, Erlmeier F, Steffens S, Steinestel J, ...
  • 33.Ohlmann C-H, Özgür E, Schrader AJ, Konrad L, Hofmann R, ...
  • 34.Xing T, Wang B, Song Y, Zhang S, Ma L. ...
  • 35.Shen Z, Wu A, Chen X. Current detection technologies for ...